Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. These cells develop in islet-like clusters grown from stem cells. Initial preclinical work in animal models of diabetes has shown that transplantation of these cells are sufficient to control blood glucose levels. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes. Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art cell delivery and immune protection strategy that can protect these cells from the patient’s immune system and allow the beta cells to function as they do in non-diabetic individuals. Implantation of the beta cell-filled device has the potential to provide a true replacement for the missing beta cells in a diabetic patient and would not require patient immunosuppression. Semma Therapeutics is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes.
Show more

Employee Rating

HQCambridge, US
Size (employees)47 (est)
Semma Therapeutics was founded in 2015 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Semma Therapeutics

Bastiano Sanna

Bastiano Sanna

David Lebwohl

David Lebwohl

Chief Medical Officer
David DiGiusto

David DiGiusto

Felicia Pagliuca

Felicia Pagliuca

Scientific Co-Founder, Vice President of Cell Biology Research and Development
Christopher G. Thanos

Christopher G. Thanos

Vice President, Delivery
Moses Goddard

Moses Goddard

Vice President, Surgery
Show more

Semma Therapeutics Office Locations

Semma Therapeutics has offices in Cambridge and Providence
Cambridge, US (HQ)
2b 450 Kendall St
Providence, US
107 117 Chapman St
Show all (2)
Report incorrect company information

Semma Therapeutics Financials and Metrics

Summary Metrics

Founding Date


Semma Therapeutics total Funding

$163 m

Semma Therapeutics latest funding size

$114 m

Time since last funding

a year ago

Semma Therapeutics investors

Semma Therapeutics's latest funding round in November 2017 was reported to be $114 m. In total, Semma Therapeutics has raised $163 m
Show all financial metrics
Report incorrect company information

Semma Therapeutics Company Life and Culture

Report incorrect company information

Semma Therapeutics Frequently Asked Questions

  • When was Semma Therapeutics founded?

    Semma Therapeutics was founded in 2015.

  • Who are Semma Therapeutics key executives?

    Semma Therapeutics's key executives are Bastiano Sanna, David Lebwohl and David DiGiusto.

  • How many employees does Semma Therapeutics have?

    Semma Therapeutics has 47 employees.

  • Who are Semma Therapeutics competitors?

    Competitors of Semma Therapeutics include InVivo Therapeutics, Idera Pharmaceuticals and Akebia Therapeutics.

  • Where is Semma Therapeutics headquarters?

    Semma Therapeutics headquarters is located at 2b 450 Kendall St, Cambridge.

  • Where are Semma Therapeutics offices?

    Semma Therapeutics has offices in Cambridge and Providence.

  • How many offices does Semma Therapeutics have?

    Semma Therapeutics has 2 offices.